Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIASPAN vs ATROMID-S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.
Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.
Primary dyslipidemia and mixed dyslipidemia as an adjunct to diet,Hypertriglyceridemia in patients at risk of pancreatitis,Reduction of risk of myocardial infarction in patients with hyperlipidemia and history of MI,Secondary prevention of cardiovascular events in combination with statin,Off-label: Prevention of pellagra (niacin deficiency)
Type III hyperlipoproteinemia,Hypertriglyceridemia (Fredrickson types IV and V) not responsive to diet
Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.
500 mg to 1 g orally twice daily. Maximum dose 2 g/day.
Terminal half-life is 20-45 minutes (immediate-release) but due to prolonged release formulation of Niaspan, the half-life is extended to 2-4 hours for total nicotinic acid and 12 hours for nicotinuric acid, allowing once-daily dosing.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 12-24 hours in renal impairment.
Primarily hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major pathway, saturable) and conversion to nicotinamide adenine dinucleotide (NAD). Minor metabolism via oxidation to N-methylnicotinamide and other metabolites.
Hepatic via glucuronidation and oxidation; major metabolite is clofibric acid.
Primarily renal (60-76% as unchanged drug and metabolites). Hepatic metabolism is extensive; less than 2% excreted in feces.
Primarily renal excretion as glucuronide conjugates; approximately 60-70% of the dose is excreted in urine, 20-30% in feces via biliary elimination.
<20% bound to plasma proteins (mainly albumin). Binding is negligible at therapeutic concentrations.
>95% bound to plasma proteins, primarily albumin.
Approximately 0.5 L/kg (around 35 L in a 70 kg adult), indicating distribution into total body water.
0.11-0.14 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Oral (extended-release): ~60-76% due to extensive first-pass metabolism. Bioavailability is dose-dependent and saturable at higher doses.
Oral: approximately 60-70% due to first-pass metabolism; administered as clofibrate (prodrug) which is hydrolyzed to active clofibric acid.
No specific dose adjustment provided by manufacturer; use with caution in patients with renal impairment; avoid in patients with severe renal impairment or nephrotic syndrome.
GFR 30-59 m L/min: 500 mg twice daily. GFR 15-29 m L/min: 250 mg twice daily. GFR <15 m L/min: avoid use.
Contraindicated in patients with significant or unexplained hepatic dysfunction; use with caution in patients with Child-Pugh class A, avoid in Child-Pugh class B or C.
Child-Pugh Class B or C: avoid use or reduce dose by at least 50%; not recommended in severe hepatic impairment.
Safety and efficacy not established in pediatric patients; not recommended for use.
Not recommended; safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended; monitor for adverse effects such as myopathy and hepatotoxicity; initiate at low end of dosing range.
Start at lower end of dosing range (500 mg twice daily). Monitor renal function; adjust dose based on GFR.
No FDA black box warning.
None
Hepatotoxicity: elevated liver enzymes, rare severe hepatotoxicity; avoid in patients with active liver disease,Flushing: prostaglandin-mediated, can be reduced by taking aspirin or starting with low doses,Hyperglycemia: may increase blood glucose, use with caution in diabetic patients,Hyperuricemia: may precipitate gout, monitor uric acid,Gastrointestinal effects: can cause peptic ulcer, use caution with history of GI bleeding,Cardiovascular: may cause hypotension, especially with concurrent use of antihypertensives
Hepatotoxicity,Cholelithiasis,Renal impairment dose adjustment,Rhabdomyolysis risk with statins,Malignancy risk (hepatic, GI)
Active liver disease or unexplained transaminase elevations,Active peptic ulcer disease,Arterial bleeding,Hypersensitivity to niacin or any component of the formulation
Hypersensitivity to clofibrate,Active liver disease,Severe renal dysfunction,Primary biliary cirrhosis,Pregnancy
Avoid alcohol, hot beverages, and spicy foods near dose time as they can worsen flushing. Take with a low-fat snack (e.g., apple, rice cakes) to reduce gastrointestinal upset and flushing. Avoid high-fat meals which may increase risk of flushing. Grapefruit juice has no significant interaction but other fruit juices have not been studied; advise moderate intake.
High-fat meals may reduce absorption; consistent timing of administration with food is recommended. Grapefruit juice may increase drug levels; avoid excessive intake. Alcohol may exacerbate hepatotoxicity.
Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregnant women. Niacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is no evidence of teratogenicity in humans at recommended doses, but high doses may cause fetal harm.
FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit outweighs risk. Second and third trimesters: May cause fetal harm due to placental transfer and potential for reduced fetal growth.
Niacin is excreted in human breast milk in amounts that are likely comparable to maternal plasma levels. The milk-to-plasma (M/P) ratio for niacin is approximately 1.0. The American Academy of Pediatrics considers niacin compatible with breastfeeding at usual dietary intakes, but high pharmacological doses should be avoided due to potential adverse effects in the infant, such as flushing and gastrointestinal disturbances.
Excreted into breast milk in low amounts; M/P ratio not established. Due to potential for serious adverse effects in infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No specific dose adjustments are recommended for niacin during pregnancy due to lack of data on pharmacokinetic changes. However, doses should be kept at the lowest effective level and used only when clearly needed. There is no evidence that pregnancy alters niacin clearance or requires dose modification.
No specific dosing adjustments recommended due to lack of data. However, pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may necessitate careful monitoring and empiric dose adjustments based on clinical response and adverse effects.
Niacin extended-release (NIASPAN) causes flushing, which can be mitigated by taking aspirin 30 minutes before dosing, avoiding alcohol and hot beverages at time of dosing, and initiating at low dose with gradual titration. Liver function tests must be monitored; elevation >3x ULN requires discontinuation. NIASPAN can exacerbate gout by increasing uric acid levels; check uric acid at baseline and periodically. Use with caution in diabetes as it may increase glucose levels. Avoid in patients with active liver disease, unexplained transaminase elevations, or peptic ulcer disease.
ATROMID-S (clofibrate) is a fibric acid derivative primarily indicated for hyperlipidemia but its use is now limited due to increased non-cardiovascular mortality and cholelithiasis risk. Monitor liver function and prothrombin time (potentiates warfarin). Not first-line; consider statins or fibrates like fenofibrate.
Take NIASPAN at bedtime with a low-fat snack to reduce flushing.,Do not take on an empty stomach; avoid alcohol and hot drinks near dose time.,Flushing may occur but usually decreases over weeks; can take aspirin 30 minutes prior to dose.,Do not miss doses; if a dose is missed, do not double up the next day.,Common side effects include flushing, itching, and tingling; report severe or persistent effects.,Your doctor will monitor blood glucose, uric acid, and liver function regularly.,Do not substitute with other niacin preparations without doctor approval.
Take with meals to reduce gastrointestinal upset.,Report unexplained muscle pain, tenderness, or weakness; may indicate myopathy.,Avoid alcohol as it may increase liver enzyme elevations.,Notify your doctor if you develop gallstones symptoms (e.g., right upper abdominal pain, nausea).,Use effective contraception as clofibrate may cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIASPAN vs ATROMID-S, answered by our medical review team.
NIASPAN is a Antilipemic agent that works by Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.. ATROMID-S is a Antilipemic Agent that works by Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIASPAN and ATROMID-S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIASPAN is: Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.. The standard adult dose of ATROMID-S is: 500 mg to 1 g orally twice daily. Maximum dose 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIASPAN and ATROMID-S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIASPAN is classified as Category C. Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregna. ATROMID-S is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit out. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.